您好，欢迎访问广东省农业科学院 机构知识库！
广东省农业科学院机构知识库

全部

  • 全部
  • 标题
  • 学者
  • 机构
  • 关键词

Augment proteasome inhibitor efficacy activates CD8+T cell-mediated antitumor immunity in breast cancer

文献类型： 外文期刊

作者： Tang, Dongyang 1 ; Lin, Shiqi 1 ; Zhou, Jingbo 1 ; Lei, Josh Haipeng 1 ; Shao, Fangyuan 1 ; Sun, Heng 1 ; Chu, Xiangpeng 1 ; Li, Ling 1 ; He, Lin 1 ; Qiao, Yunfeng 1 ; Xu, Xiaoling 1 ; Deng, Chu-Xia 1 ;

作者机构： 1.Univ Macau, Fac Hlth Sci, Canc Ctr, Macau, Peoples R China

2.Univ Macau, Fac Hlth Sci, Ctr Precis Med Res & Training, Macau, Peoples R China

3.Guangdong Acad Agr Sci, Rice Res Inst, Guangzhou, Peoples R China

4.Univ Macau, MoE Frontiers Sci Ctr Precis Oncol, Macau, Peoples R China

期刊名称：CELL REPORTS MEDICINE （ 影响因子：10.6； 五年影响因子：10.8 ）

ISSN： 2666-3791

年卷期： 2025 年 6 卷 7 期

页码：

收录情况： SCI

摘要： Although three proteasome inhibitors are used for liquid tumor treatment, their effectiveness against solid tumors remains inadequate. To address this issue, we employ a drug combination strategy and discover that ammonium tetrathiomolybdate (TM) and AMD3100 can sensitize solid cancer cell lines to proteasome inhibitors. Mechanistically, we find that TM and AMD3100 reduce proteasome activity by decreasing the protein level of PSMB5. This reduction occurs through the activation of the AMP-activated protein kinase (AMPK) pathway, which inhibits STAT3 phosphorylation. Notably, our in vivo studies reveal that drug combinations retard tumor growth dependent on CD8+ T cells. The combination of bortezomib with TM or AMD3100 induces cancer cell antigen presentation and the production of CCL5, which together stimulate the recruitment and generation of cytotoxic CD8+ T cells. This study identifies synergistic lethal pairs that enhance the effectiveness of bortezomib-centered therapy for breast cancer treatment in a way relied on intact immune system.

  • 相关文献
作者其他论文 更多>>
置顶
购物车
反馈

© 京ICP备09089781号-29 主办单位：广东省农业科学院

学术资源： 中国农业科学院 农业专业知识服务系统 农科联盟资源共建共享平台 中国农业科技文献与信息服务平台 中国农业期刊集成服务平台